Status:
UNKNOWN
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Lead Sponsor:
Opsidio, LLC
Collaborating Sponsors:
Innovaderm Research Inc.
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared...
Eligibility Criteria
Inclusion
- Subject has clinically confirmed diagnosis of active AD
- Subject has at least a 6-month history of AD
- Subject is willing to use effective birth control
Exclusion
- Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
- Subject has any clinically significant medical condition that would put the subject at undue risk or interfere with interpretation of study results.
- Subject has used dupilumab within 26 weeks prior to Day 1
- Subject has used tralokinumab within 12 weeks prior to Day 1
Key Trial Info
Start Date :
October 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06101823
Start Date
October 25 2023
End Date
June 1 2025
Last Update
May 7 2024
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Cahaba Dermatology & Skin Health Center
Birmingham, Alabama, United States, 33607
2
First OC Dermatology Research
Fountain Valley, California, United States, 92708
3
Axon Clinical Research
Inglewood, California, United States, 90301
4
University Clinical Trials
San Diego, California, United States, 92123